IL6 and triple-negative breast carcinoma: Accordingly, in the aforementioned study on triple-negative breast cancer lines, silencing of the cGAS-STING-IL6-STAT3 axis by tocilizumab, a monoclonal antibody inhibiting the IL6-receptor, selectively reduced proliferation and viability of cells carrying high chromosomal instability.